OmniAb, Inc.
Marie-Cecile Van De Lavoir has an extensive work history in the biotechnology and pharmaceutical industry. Marie-Cecile currently holds the position of Senior VP Technical Operations & Animal Genetics at OmniAb, Inc. since November 2022. Prior to this, they served as Vice President of Operations at Ligand Pharmaceuticals from October 2017 to November 2022.
From 2008 to 2017, Van De Lavoir was the COO & Co-Founder of Crystal Bioscience. Marie-Cecile also worked as a Staff Scientist at Origen Therapeutics from September 1999 to May 2008. Earlier in their career, they were a Postdoctoral Fellow at the University of California, San Francisco from August 1996 to September 1999. Marie-Cecile started their professional journey as a Staff Veterinarian at Utrecht University from January 1986 to July 1988.
Marie-Cecile Van De Lavoir began their education in 1977 at Utrecht University, where they pursued a degree in Veterinary Medicine. Marie-Cecile successfully completed their studies in 1985, obtaining the DVM degree.
In 1988, Marie-Cecile Van De Lavoir attended Cornell University, focusing on Reproductive Physiology. Although the specific degree obtained during their time at Cornell University is not mentioned, it is clear that they furthered their knowledge in this field.
From 1989 to 1996, Marie-Cecile Van De Lavoir attended the University of Guelph, where they pursued both an MSc and a PhD in Embryology. This period allowed their to specialize and conduct extensive research in this field.
Based on the provided information, Marie-Cecile Van De Lavoir's education history includes a DVM degree in Veterinary Medicine from Utrecht University, additional studies in Reproductive Physiology from Cornell University, and an MSc and PhD in Embryology from the University of Guelph.
This person is not in the org chart
OmniAb, Inc.
The OmniAb discovery platform provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence (BI) of our proprietary transgenic animals, including OmniRat,OmniChicken and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur features unique structural attributes of cow antibodies for complex targets. OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput microfluidic-based single B cell screening and deep computational analysis of next-generation sequencing datasets to identify fully human antibodies with superior performance and developability characteristics. An established core competency focused on ion channels and transporters further differentiates our technology and creates opportunities to further leverage across modalities, including antibody-drug conjugates and others. The OmniAb suite of technologies and differentiating computational capabilities and BI features are combined to offer a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry. For more information, please visit www.omniab.com.